PATIENTS AND METHODS
The Blue Health Intelligence (Blue Cross/ Blue Shield) database, 5 a national commercial claim-based database, was queried for the period 2009 to 2013. Included subjects consisted of all women aged 18 years or older with a claim filed for breast reconstruction. Current Procedural Terminology codes were used to identify the method of reconstruction, with codes 19357 and 11970 used for tissue expanders and code 19364 used for free flap-based reconstruction. The modifier 50 was used to identify bilateral procedures. Both immediate and delayed reconstructions were included. Patients with pedicled flaps, hybrid reconstructions, and unknown claim status were excluded.
Episodes of reconstruction were sorted by method, laterality, physician payment, and year of service. The yearly incidence of breast reconstruction was trended over the 5-year period using Poisson regression, reporting incidence rate ratios. In addition, the ratios of tissue expander to free flap-based reconstruction cases were compared to assess relative growth for any given year. Physician payment trends were analyzed using linear regression. To compare physician reimbursements at the aggregate level of tissue expander or free flap-based reconstruction, bilateral reimbursements were adjusted to an equivalent unilateral payment, given that bilateral cases reimbursed less than twice the unilateral amount. This multiplicative factor was determined for tissue expander and free flap-based reconstruction cases after comparing all payments over the 5-year period. To account for inflation, all reimbursements were transformed into 2013 dollars using the Consumer Price Index according to the U.S. Bureau of Labor Statistics. 6 To illustrate payment variations between the two methods, the magnitude and shape of payment variations were displayed with whisker box plots. Coefficients of variation were determined by dividing the standard deviation of physician payments by the mean. Statistical analyses were completed with Stata 14 (Stata Corp LLC, College Station, Texas). All statistical tests were considered significant for values of p < 0.05. The following study was exempt from institutional review board evaluation.
RESULTS
During the 5-year study period, there were 21,259 episodes of breast reconstruction, growing from 3686 cases/year in 2009 to 4924 cases/ year in 2013 (Tables 1 and 2 and Fig. 1 ). Tissue expander cases saw a significant increase, with an incidence rate ratio of 1.09 (p < 0.001), compared to no appreciable change in free flapbased reconstruction cases, with an incidence rate ratio of 1.02 (p = 0.222). Parsing by laterality, the incidence of both unilateral and bilateral tissue expander cases increased, with incidence rate ratios of 1.01 (p = 0.047) and 1.16 (p < 0.001), respectively. Although the overall free flap incidence did not increase, when stratifying by laterality, bilateral cases increased, with an incidence rate ratio of 1.16 (p < 0.001). Thus, unilateral free flap cases declined over the period, with an incidence rate ratio of 0.96 (p = 0.030). Unilateral To compare tissue expander and free flap payments in aggregate regardless of laterality, bilateral cases were normalized to unilateral dollars based on an actuarial multiplicative factor. Bilateral tissue expander cases reimbursed 1.32 times more than unilateral cases, whereas bilateral free flap cases reimbursed 1.61 times more than unilateral cases. After adjustment, the total growth in tissue expander mean physician payments was 6.5 percent (from $2232 to $2378) compared with −1.8 percent (from $3858 to $3788) for free flap mean payments. Comparing the growth of mean physician payments for tissue expander cases relative to free flap cases, there was an 8.4 percent increase (from 0.58 to 0.63).
Linear modeling of physician payments per case per year showed significant increases for total tissue expander reimbursements (p < 0.001); this held true even when stratifying laterality (unilateral, p < 0.001; bilateral, p = 0.018). Normalized free flap payments showed no significant growth (p = 0.422), which was factual even when parsing laterality (unilateral, p = 0.443; bilateral, p = 0.442) ( Tables 3 and 4) .
Examining differences across all physician payments by year demonstrated greater variation for free flap compared to tissue expander payments (Fig. 2) . The overall coefficient of variation was considerably lower for tissue expander payments at 0.59 compared to 1.08 for free flap payments. Both payment distributions were rightward skewed toward higher payments; however, free flap payments showed a greater deviation. The overall interquartile range (25th to 75th percentile) for Finally, determining whether adjusted median physician payments were associated with the incidence of reconstructive method, linear models showed a significant trend for median tissue expander payments (coefficient, 5.08; 95 percent CI, 0.75 to 11.23; p = 0.044) (Fig. 3) . There was no correlation with the incidence of free flap cases and median physician payments for free flap cases (coefficient, 0.25; 95 percent CI, −2.04 to 2.55; p = 0.747).
DISCUSSION
Data from the Blue Health Intelligence claims database mirror findings of national outcomes data sets 7, 8 showing an overall increase in the incidence of breast reconstruction with a simultaneous rise in both prosthetic and bilateral variants. For the first time, there is documentation of bilateral tissue expander cases surpassing unilateral tissue expander reconstructions-a finding that likely correlates with a well-documented expansion in nationwide rates of contralateral prophylactic mastectomy. 9 Although free flap-based reconstruction cases grew in total over the period, only the subset of bilateral free flap cases increased significantly. Furthermore, the change in case mix between tissue expanders and free flaps showed continual relative gains for tissue expander cases, nearing a 11:1 ratio to autologous flaps in the late study period. This is the first published national claims analysis looking at physician payments-not chargesfor the two most common methods of immediate breast reconstruction. The results support prior single-institution data showing a rise in surgeon payments for tissue expander cases, with stagnation in payments for free flap cases. 4 The Blue Health Intelligence data paralleled this, with both unilateral and bilateral tissue expander mean physician payments increasing significantly over the study period, whereas free flap payments, regardless of laterality, showed no significant changes. Payment variation per case, as expressed by the coefficient of variation and interquartile ranges, was much greater for free flap cases than for tissue expander cases, demonstrating wide disparities in flap reimbursements.
Associations between surgery incidence and payment (Fig. 3) should be interpreted cautiously, as causality may run in either direction, depending on interpretation of economic factors. Considering neoclassical economic theory, 10 the rising tissue expander incidence was found to correlate with rising payments, implying that tissue expander demand may be driving the payment increase. This is substantiated by consideration of other relevant economic factors, such as the stable supply of reconstructive surgeons. 11 Thus, the supply curve is likely unchanged against rising demand. An important nonmarket force that impacts physician reimbursements is the relative value unit schedules proposed by the American Medical Association's Relative Value Scale Update Committee. 12 Although this study examined a commercial payer, Medicare fee schedules often directly influence commercial rates. 13 Interestingly, in this claims database, tissue expander payments rose despite no corresponding increase in the relative value unit schedule. There was actually a decline in the relative value units for tissue expander cases in 2010 from 21.07 to 18.50, suggesting that the rise in reimbursement documented herein has resulted principally from market forces. 14 The implications for free flap-based reconstruction and associated physician payments are less clear. The absent growth in the incidence of free flap cases or free flap payments implies market equilibrium. Thus, a balance in supply and demand is the most parsimonious cause for price stability, with other explanations such as price ceilings unlikely. 15 As with considerations for tissue expander payment trends, there is no evidence to indicate fluctuations in the supply of reconstructive surgeons. 11 In fact, it could be argued that the shift to perforator flaps has led to an inadequate supply of microsurgeons as a cause for the relatively low case number, but this would only serve to raise payments. Looking at nonmarket influences on physician payment, there was no change in the relative value unit schedule for free flap reconstructions over the study period. The relative value unit schedule showed a slight bump in 2009, from 42.40 to 42.58, with no changes thereafter. 14 The choice of reconstruction method does not occur in a vacuum, as surgeons help patients decide on the best operation in a shared decision-making process. 16 The current pattern of rising prosthetic reconstruction is well supported by patient interest in prosthetic techniques. Features that favor implants include but are not limited to the following: greater requests for bilateral reconstructions, patient desire for shorter recovery, and decreasing relative contraindications, such as radiation therapy.
1-3 Despite these patient-driven factors, the relative increase in payments for prosthetic reconstruction could persuade surgeons to favor this operation, with all factors being equal. Single-institution data 17 showed a considerable financial disparity between prosthetic and autologous reconstruction relative to operative labor; delayed prosthetic reconstruction reimbursed over eight times more per hour of operative time than delayed autologous free tissue transfer. Although the current study did not account for office-related procedures in the 90-day global period, including the physician time required to perform tissue expansion, the hourly tissue expander reimbursement was many times greater than the hourly rate for auto logous reconstruction. Furthermore, no consideration was given to the additional revenue obtained from replacing tissue expanders with permanent implants. Therefore, it is plausible that at some remuneration threshold the opportunity cost of providing autologous reconstruction could sway surgeons to consider the alternative method.
Ways to ensure that autologous tissue remains widely available include both policy and market considerations. Looking to policy, suggestions include adopting value-based payment models that reimburse based on quality outcomes, such as the BREAST-Q, appreciating that autologous reconstruction has demonstrated greater long-term patient satisfaction. 18 Simultaneously, these outcomes must be reliably communicated to patients who choose between breast reconstruction techniques. In addition, update of the current relative value unit schedule for free flap-based reconstruction could be achieved through surveys to ensure that current reimbursement accurately reflects time and effort.
Nonpolicy considerations could leverage the wide variation in free flap payments shown in this study. Reconstructive microsurgeons received payments that varied by $2243 between the 25th and 75th percentiles. Although this analysis considered the Blue Health Intelligence database in aggregate, in reality the Blue Health Intelligence database is composed of over 120 unique markets, which may be sensitive to varying patient and physician preferences for free flap cases. Moreover, the greater variation in payments for free flaps can be seen in a positive light, suggesting there is room for negotiations between payers and providers to remunerate the increased labor for free flaps.
Limitations
Interpretations of this study are generated by a single commercial payer and thus represent a potential source of sample bias. Multiple commercial payers exist throughout the United States and participate to varying degrees in markets. In addition, the demographic profile of patients represented in the database may not accurately reflect the current profile of patients who undergo breast reconstruction in the United States. That said, the Blue Health Intelligence database includes 165 million Americans, representing a significant sample (nearly half) of the U.S. population. 5 Regarding determinations of statistical significance, our data were modeled using Poisson and linear regression. Given the short time horizon, these trends could be altered by market fluctuations in subsequent years. For the payment data, only linear functions (which were reasonable approximations given the data distribution) were assessed; however, it is also possible that the 5-year snapshot is part of a greater nonlinear function. By definition, this study cannot analyze data outside the captured interval. Many assumptions are required to apply market equilibrium theory to breast reconstruction volume and payment; notably, a direct relationship between the consumer (patient) and supplier (surgeon) needs to be present. Third-party payers (e.g., commercial insurance) intermediate the exchange of payments, which confounds the ability of patient demand to directly influence payments. Furthermore, health economists have written extensively 19 on the limitations of treating patients as rational consumers, given significant information asymmetries and the ability of physicians to induce demand. 20 Nonetheless, patient demand can still affect payments through insurers competing for physician contracts.
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CONCLUSIONS
Use of a commercial claims database demonstrates that tissue expander reimbursements increased over a period during which reimbursements for free flap-based reconstruction plateaued, perhaps reflective of greater demand for prosthetic techniques. Stagnation in autologous reconstruction payments could at some point perversely promote the alternative technique if the opportunity cost of performing these procedures is too great. Large payment variations documented for autologous reconstruction represent an opening for negotiation with payers that should be bolstered by objective quality data from patient-reported outcomes. Further investigations exploring economic drivers of reconstructive method are needed to ensure equitable access to all reconstructive methods. 
